A major focus of the Diekman lab is to develop new strategies to limit age-related osteoarthritis (OA). The lab uses genetically-engineered mouse models to investigate the development of cellular senescence in joint tissues with physiologic aging. One goal of this work is to determine whether “senolytic” compounds that induce selective apoptosis in senescent cells will mitigate OA development. Our group has also developed genome-editing protocols for primary human chondrocytes to produce single-cell derived colonies with homozygous knockout of target genes. We are using engineered tissues from these cells to dissect the mechanism of genes implicated in OA development by genome-wide association studies, as well as coupling these technologies to high throughput screening approaches for OA drug discovery.